{"protocolSection":{"identificationModule":{"nctId":"NCT01556854","orgStudyIdInfo":{"id":"2011BAI08B02-01"},"organization":{"fullName":"Ministry of Science and Technology of the People´s Republic of China","class":"OTHER_GOV"},"briefTitle":"Comparative Effectiveness of Neuroprotectants on Acute Ischemic Stroke","officialTitle":"Comparative Effectiveness of Different Neuroprotectants Among Patients With Acute Ischemic Stroke in Clinical Practice","acronym":"CER"},"statusModule":{"statusVerifiedDate":"2012-03","overallStatus":"UNKNOWN","lastKnownStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-07"},"primaryCompletionDateStruct":{"date":"2013-11","type":"ESTIMATED"},"completionDateStruct":{"date":"2014-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2012-03-13","studyFirstSubmitQcDate":"2012-03-15","studyFirstPostDateStruct":{"date":"2012-03-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-03-15","lastUpdatePostDateStruct":{"date":"2012-03-16","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"yongjun wang","investigatorTitle":"Beijing Tiantan hospital","investigatorAffiliation":"Ministry of Science and Technology of the People´s Republic of China"},"leadSponsor":{"name":"yongjun wang","class":"OTHER_GOV"}},"descriptionModule":{"briefSummary":"The primary objective of this study is to compare effectiveness of five different neuroprotectants, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.\n\nThe secondary objectives of the study are as follows:\n\n* To compare safety of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.\n* To compare cost-effectiveness of five different neuroprotectents, including butylphthalide, edaravone, citicoline, cerebrolysin, and piracetam, among patients with acute ischemic stroke.","detailedDescription":"Study Population:The study population will consist of consenting patients who are on neuroprotectant injection for the treatment of acute IS during hospitalization. Hospitals may contribute differing numbers of patients to the total sample size. Primary analyses will be conducted on the total sample size only.\n\nAssessment of Outcomes:The outcome measures in this study include effectiveness, safety and cost measures."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"],"keywords":["ginkgo leaves","butylphthalide","edaravone","citicoline","cerebrolysin","piracetam","Neuroprotectants"]},"designModule":{"studyType":"OBSERVATIONAL","designInfo":{"timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":20000,"type":"ESTIMATED"}},"outcomesModule":{"primaryOutcomes":[{"measure":"Effectiveness Outcome Measures","description":"* The severity of neurological impairment evaluated by the NIHSS • Disability by mRS\n* All cause mortality\n* In-hospital recurrence and recurrence at 3 month post discharge\n* In-hospital complications\n* Cognitive disorder evaluated by MMSE\n* Quality of Life evaluated by EQ5D","timeFrame":"3 years"}],"secondaryOutcomes":[{"measure":"Safety Outcome Measures","description":"* death\n* prolonged inpatient hospitalization\n* a life-threatening experience (that is, immediate risk of dying)\n* persistent or significant disability/incapacity\n* or is considered significant by the physician for any other reason.","timeFrame":"3 years"},{"measure":"Cost-effectiveness Outcome Measures","description":"* Medical cost at discharge\n* Drug cost at discharge\n* Neuroprotectents cost at discharge\n* Administration cost at discharge\n* Medical cost at 3 month post discharge\n* Drug cost at 3 month post discharge","timeFrame":"2011.7-2014.6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* Ischemic stroke confirmed by brain CT or MRI within 14 days of the index event\n* Neuroprotectents administrated during hospitalization\n* Direct admission based on physician evaluation or arrival through the emergency department\n* Ability of patient or legally authorized representative (primarily spouse, parents, adult children, otherwise indicated) to provide informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"The study population will consist of consenting patients who are on neuroprotectant injection for the treatment of acute IS during hospitalization.","samplingMethod":"PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Tiantan hospital","status":"RECRUITING","city":"Beijing","state":"Beijing","zip":"100050","country":"China","contacts":[{"name":"Yilong Wang, Doctor","role":"CONTACT","phone":"00861067098222","email":"yilong528@Gmail.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M1831","name":"Edaravone","relevance":"LOW"},{"id":"M6461","name":"Cytidine Diphosphate Choline","relevance":"LOW"},{"id":"M351658","name":"Cerebrolysin","relevance":"LOW"},{"id":"M352286","name":"3-n-butylphthalide","relevance":"LOW"},{"id":"M13470","name":"Piracetam","relevance":"LOW"},{"id":"M20463","name":"Neuroprotective Agents","relevance":"LOW"},{"id":"T167","name":"Ginkgo","relevance":"LOW"}],"browseBranches":[{"abbrev":"NeuroAg","name":"Neuroprotective Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"NootAg","name":"Nootropic Agents"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"HB","name":"Herbal and Botanical"}]}},"hasResults":false}